Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease.

International journal of molecular sciences - 16 Sept 2021

Dakhel Sheila, Lizak Christian, Matasci Mattia, Mock Jacqueline, Villa Alessandra, Neri Dario, Cazzamalli Samuele

Abstract excerpt

Antibody-cytokine fusion proteins (immunocytokines) are gaining importance for cancer therapy, but those products are often limited by systemic toxicity related to the activity of the cytokine payload in circulation and in secondary lymphoid organs. Tumor necrosis factor (TNF) is used as a pro-inflammatory payload to trigger haemorrhagic necrosis and boost anti-cancer immunity at the tumor site. Here we describe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cricetulus

Share to Fibronectins

Share to Fluorescent Antibody Technique

Share to Immunotherapy

Share to Receptors, Tumor Necrosis Factor

Share to Receptors, Tumor Necrosis Factor, Type I

Source

Open in PubMed Open full text

Identifiers

PMID: 34576184
DOI: 10.3390/ijms221810020
PMCID: PMC8469155

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease.PMID 34576184Read ↗

Development and Characterization of a Potent Tumor Necrosis Factor-Alpha Blocking AgentSemantic proximity Read ↗

A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification.Semantic proximity Read ↗

Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseasesSemantic proximity Read ↗

Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journeySemantic proximity Read ↗

De novo masking domains that gate TNF-family ligand assembly and activitySemantic proximity Read ↗

Engineering murine GITRL for antibody-mediated delivery to tumor-associated blood vesselsSemantic proximity Read ↗

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 <sup>+</sup> T cell activity and synergizes with immune check-point inhibitorsSemantic proximity Read ↗

A New Venue of TNF TargetingSemantic proximity Read ↗

A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo.Semantic proximity Read ↗

TNF biology, pathogenic mechanisms and emerging therapeutic strategiesSemantic proximity Read ↗

An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy.Semantic proximity Read ↗

Tumor necrosis factor (TNF)-functionalized nanostructured particles for the stimulation of membrane TNF-specific cell responses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.